ORALLY ACTIVE MANNOSIDES SUBVERT ANTIBIOTIC RESISTANCE IF E COLI IN BLADDER

如果膀胱中有大肠杆菌，口服活性甘露糖苷可消除抗生素耐药性

• 批准号: 8361464
• 负责人: SCOTT J. HULTGREN
• 金额: $ 1.24万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-01-01 至 2011-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8361464
• 关键词: Antibiotic Resistance; Bladder; Escherichia coli; Funding; Grant; Health; Mannosides; Mass Spectrum Analysis; Multi-Drug Resistance; National Center for Research Resources; Principal Investigator; Research; Research Infrastructure; Resistance to infection; Resources; Source; Trimethoprim-Sulfamethoxazole; United States National Institutes of Health; Urinary tract infection; Uropathogen; antimicrobial; biomedical resource; cost; pathogen

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. Proliferation of antibiotic-resistant pathogens has been described as an impending health crisis1. This is increasingly evident for urinary tract infections (UTI) where resistance to first-line empiric therapy with trimethoprim-sulfamethoxazole (TMP-SMZ) by uropathogens complicates treatment, and drives use of alternate antimicrobial agents2. As a consequence, multidrug-resistant uropathogens are on the rise, making the straightforward treatment of UTI increasingly difficult.

这个子项目是利用这些资源的众多研究子项目之一